Pervasis starts phase I/II trial of cellular PAD therapy
This article was originally published in Clinica
Executive Summary
Pervasis Therapeutics has started enrolling patients in its phase I/II study of its peripheral arterial disease (PAD) therapy. The product, an injectable formulation of tissue-engineered allogeneic endothelial cells within a collagen matrix, is called PVS-10200.